Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeBIOTECHNOLOGYNeuroSense Therapeutics Announces Encouraging Interim Results of Clinical Study in ALS

NeuroSense Therapeutics Announces Encouraging Interim Results of Clinical Study in ALS

September 9, 2020

NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow ALS progression, announced today that PrimeC was safe and well-tolerated in the interim analysis of study NST002, a Phase IIa study conducted by Principal Investigator Prof. Vivian Drory in Israel at Tel-Aviv Sourasky Medical Center (TASMC).

Trends toward slowing of disease progression were seen both in ALSFRS-R and Vital Capacity. These trends were noted in the last 3 months of the 6-month study.

NeuroSense Therapeutics notes the study, containing 15 patients, is scheduled to continue for an additional 6 months.

Alon Ben-Noon, CEO of NeuroSense Therapeutics, added: “We are very encouraged by the interim results and are now preparing for more analyses that may reveal additional layers of observations. We intend to initiate an additional clinical trial by the beginning of 2021 with the new PrimeC advanced formulation.”  Jeremy Shefner, MD, PhD, Chair of Neurology at the Barrow Neurological Institute and advisor to the NeuroSense program, said: “These clinical signals, in conjunction with the very promising preclinical results in multiple ALS models, clearly warrant further investigation in a larger, placebo-controlled study.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Adam S. Epstein New CEO of AliMed, Inc.

In his prior role as Chief Commercial Officer, Epstein directed all customer-facing, demand generation and product development activities. Under his new leadership, AliMed will continue to build a robust portfolio of contracted positions with major, national GPO’s, IDN’s, and Distribution partners to drive sales growth.

Tony Collins Appointed CFO of Xenter

“Xenter is building a platform for medical innovations that is transformational. The only way we can achieve our objectives is if we have great leaders like Tony Collins leading our company,” stated Richard J. Linder, Founder, Chairman & CEO of Xenter, Inc. “Tony brings incredible depth and experience to his new role as Chief Financial Officer.

HistoSonics Receives FDA “Breakthrough Device Designation” for Novel Sonic Beam Therapy

Histotripsy of the liver provides clinicians the first automated external beam therapy using acoustic energy to mechanically destroy and liquefy tissue in the liver without incisions, ionizing radiation or heat.

Scott Sexton Appointed President at FIGUR8

"Scott brings to FIGUR8 30 years of workers' compensation, casualty, disability, and commercial health experience, most recently serving as a market leader for CorVel's national carrier practice sales team," said Nan-Wei Gong, CEO, and co-founder of FIGUR8.

Endolumik Inc. of Morgantown Secures $175,000 Angel Investment from Country Roads Angel Network

Endolumik, Inc. was founded in May 2020 by Mara McFadden, chief executive officer, and Dr. Nova Szoka, inventor of the surgical device.

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced...

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

By using this website you agree to accept Medical Device News Magazine Privacy Policy